EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling

Yin Ku, Yao Zheng, Yu Ding, Peichuan Zhang, Xiaoqing Wu, Yaohui Chen iD

International Journal of Molecular Sciences · 08.08.2026 · 27 (16) · 7119

DOI: 10.3390/ijms27167119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.08.2026. Verfasst von Yin Ku und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, No.37, Guoxue Valley, Wuhou District, Che…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Lung Neoplasms, Tumor Microenvironment, Cyclin-Dependent Kinase 6. Die Arbeit nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "RongPiao" innovated Program of Chengdu, “RongPiao” innovated Program of Chengdu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have long been characterized as classical antiproliferative agents that induce G1 cell cycle arrest by blocking the phosphorylation of the retinoblastoma protein (Rb). However, recent studies in lung cancer have expanded this paradigm, revealing a functional transition from exclusive tumor suppression to the profound remodeling of the tumor microenvironment (TME) to enhance antitumor immunity. This review systematically outlines the genomic aberrations of the CDK4/6-Rb axis across lung cancer subtypes and dissects its immunomodulatory networks. These encompass the activation of effector T cells, the alleviation of immunosuppression mediated by regulatory T cells (Tregs), and the enhancement of antigen presentation via the Cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. Furthermore, we analyze acquired resistance mechanisms, primarily focusing on p21-CDK2 bypass activation mediated by Cyclin E1 gene (CCNE1) amplification and tumor protein 53 gene (TP53) mutations. We also review clinical investigations combining CDK4/6 inhibitors with targeted therapies against driver genes, as well as immune checkpoint inhibitors in lung cancer. Notably, in the context of lung cancer, these combinatorial strategies have been primarily investigated in the second-line or subsequent settings following progression on standard platinum-based chemotherapy or immunotherapy. Finally, we propose individualized, stratified treatment strategies based on genomic and immunological biomarkers, providing a translational framework for overcoming multidrug resistance and optimizing next-generation combinatorial regimens in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Lung NeoplasmsTumor MicroenvironmentCyclin-Dependent Kinase 6Protein Kinase InhibitorsCell Cycle CheckpointsHumansAnimals

Stichwörter der Autor:innen

CDK4/6 inhibitorsacquired resistancebiomarkersnon-small-cell lung cancertumor microenvironment

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, No.37, Guoxue Valley, Wuhou District, Chengdu 610041, China.
  • Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

ORCID-Profile: Yaohui Chen

Förderung

  • "RongPiao" innovated Program of Chengdu
  • “RongPiao” innovated Program of Chengdu

Zitieren

APA

Ku, Y., Zheng, Y., Ding, Y., Zhang, P., Wu, X., & Chen, Y. (2026). Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling. International Journal of Molecular Sciences, 27(16), 7119. https://doi.org/10.3390/ijms27167119

Vancouver

Ku Y, Zheng Y, Ding Y, Zhang P, Wu X, Chen Y. Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling. International Journal of Molecular Sciences. 2026;27(16):7119. doi:10.3390/ijms27167119

BibTeX
@article{Ku2026,
  author = {Ku, Yin and Zheng, Yao and Ding, Yu and Zhang, Peichuan and Wu, Xiaoqing and Chen, Yaohui},
  title = {Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7119},
  doi = {10.3390/ijms27167119}
}
Kostenlos starten →